2023 年第一季度报告 证券代码：600227 证券简称：圣济堂 贵州圣济堂医药产业股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是√否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 2023 年第一季度报告 | 动产生的损益 | | | --- | --- | | 根据税收、会计等法律、法规的要求对当期损益进行一次性 | | | 调整对当期损益的影响 | | | 受托经营取得的托管费收入 | | | 除上述各项之外的其他营业外收入和支出 | -279,781.69 | | 其他符合非经常性损益定义的损益项目 | | | 减：所得税影响额 | | | 少数股东 ...

Financial Performance - The company's operating revenue for 2022 was ¥2,517,340,257.45, representing a 15.40% increase compared to ¥2,181,369,746.32 in 2021[23]. - The revenue from core business activities, after excluding non-core income, was ¥2,456,807,313.84, which is an 18.39% increase from ¥2,075,212,366.58 in the previous year[23]. - The net profit attributable to shareholders was -366.57 million RMB, compared to -51.87 million RMB in the previous year, indicating a significant increase in losses[24]. - The basic earnings per share decreased to -0.2165 RMB from -0.0306 RMB in 2021, reflecting a worsening financial performance[25]. - The weighted average return on equity dropped to -12.29%, a decrease of 10.67 percentage points compared to the previous year[25]. - The company's total assets at the end of 2022 were 4,616.63 million RMB, a slight increase of 0.31% from 2021[24]. - The cash flow from operating activities was 195.62 million RMB, down 29.30% from the previous year[24]. - The company reported a total revenue of -151.39 million yuan and a net loss of -182.77 million yuan, marking a shift from profit to loss compared to the previous year[35]. - The company's net assets attributable to shareholders decreased by 11.58% to 2,798.75 million RMB compared to the end of 2021[24]. Business Segments - The chemical business segment achieved revenue of 2,392.54 million RMB, a year-on-year increase of 17.08%, while the cost of goods sold rose by 36.92%[34]. - The pharmaceutical manufacturing segment experienced a decline in sales volume and revenue by 22.53% and 9.47%, respectively, due to regulatory impacts[34]. - The pharmaceutical segment generated revenue of 124.80 million yuan, a decrease of 9.53% year-on-year, with a net loss of -188.71 million yuan, exacerbated by the cancellation of procurement qualifications for key products[42]. - The company’s chemical business, primarily through its subsidiary Tongzi Chemical, has a designed capacity of 520,000 tons of urea and 300,000 tons of methanol annually[87]. - The company’s compound fertilizer sales revenue increased by 269.29% year-on-year, with a gross margin of 8.26%[172]. Market Conditions - The domestic urea market saw a price increase of 12.09% year-on-year, with an average price of CNY 2,717 per ton in 2022[52]. - Urea production in 2022 reached 56.3 million tons, a 4.84% increase from 2021, with a capacity utilization rate of 76.33%[53]. - The average price of compound fertilizer in 2022 was 3,521 RMB/ton, reflecting a year-on-year increase of 26.75%[63]. - The average price drop for selected products in the national procurement program exceeded 52%, compelling pharmaceutical companies to upgrade their operational management to maintain market presence[76]. - The market for diabetes medications in China is projected to exceed CNY 11.8 billion, with a growth rate of 11.6%[128]. Research and Development - The company filed 10 patent applications and received 30 patent grants in 2022, indicating a strong commitment to R&D and innovation[39]. - The company reported a total R&D investment of approximately 97.2 million yuan, which is 3.86% of total revenue, with capitalized R&D accounting for 0.52%[113]. - The company is focusing on the R&D of diabetes medications, including the sustained-release form of metformin and other related drugs, with a goal to expand its diabetes product line[188]. - The company has suspended the research and development of certain projects, including the Amber Acid Quge and Azilsartan raw materials, due to loss of competitive advantage and production transfer issues[141]. - The company is currently conducting process verification for Yimucao granules, aimed at treating menstrual disorders[140]. Operational Efficiency - The company completed 25 technical improvement projects in 2022, including 3 major upgrades, which effectively reduced production costs and improved energy efficiency[37]. - The company strengthened its management to improve operational efficiency, focusing on stable supply and cost control, resulting in effective management of raw material supply costs[47]. - The company is positioned as a market leader in the urea sector within Guizhou, leveraging transportation advantages over competitors using natural gas[161]. - The company has implemented energy-saving modifications to existing facilities to enhance resource utilization and align with national low-carbon policies[187]. - The company is focusing on optimizing its management systems across various departments, including administration, medical, and financial management, to enhance operational efficiency[50]. Governance and Compliance - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties during the reporting period[7]. - The company has not violated any decision-making procedures regarding external guarantees[7]. - The company has a commitment to transparency and has disclosed its annual report through multiple media channels, including the Shanghai Stock Exchange website[19]. - The company has established a complete and independent financial accounting system, ensuring no shared bank accounts with the actual controller or related enterprises[200]. - The company maintains a fully independent operational capability, with no business dependencies or competitive relationships with the actual controller's other enterprises[200]. Challenges and Risks - The company is facing risks that may adversely affect its future development strategies and operational goals, as detailed in the risk analysis section[8]. - The company has identified risks including raw material coal supply, water resource availability, and rising coal prices, which could impact production operations[193]. - The company faces significant challenges due to national "carbon peak" and "carbon neutrality" policies, requiring increased investment in energy efficiency and carbon reduction to avoid being phased out[195]. - The pharmaceutical industry is heavily influenced by government policies, with ongoing risks of product price declines due to healthcare reforms and centralized procurement policies[196]. - The company is developing multiple new drug varieties, but the lengthy and costly R&D process poses risks if market demand is not met, potentially affecting sales and profitability[196].

2022 年第三季度报告 证券代码：600227 证券简称：圣济堂 贵州圣济堂医药产业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | | 年初至报告期末 | | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 549,978,912.85 | -11.75 | 1,928,488,1 ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 1.38 billion, representing a 33.60% increase compared to CNY 1.03 billion in the same period last year[19]. - The net profit attributable to shareholders of the listed company was a loss of approximately CNY 95.73 million, compared to a profit of CNY 82.18 million in the same period last year[19]. - The net cash flow from operating activities decreased by 10.79% to approximately CNY 197.87 million, down from CNY 221.80 million in the previous year[19]. - The total assets at the end of the reporting period were approximately CNY 4.74 billion, an increase of 3.08% from CNY 4.60 billion at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company decreased by 3.01% to approximately CNY 3.07 billion, down from CNY 3.17 billion at the end of the previous year[19]. - The basic earnings per share for the first half of 2022 was -CNY 0.0565, compared to CNY 0.0485 in the same period last year[20]. - The weighted average return on net assets was -3.07%, a decline from 2.52% in the previous year[20]. - The company reported a loss of approximately CNY 100.84 million after deducting non-recurring gains and losses, compared to a profit of CNY 80.44 million in the same period last year[19]. - The company achieved a total operating revenue of 1.379 billion yuan, with a profit of -106 million yuan[37]. - The overall revenue increased by 347 million yuan, representing a year-on-year growth of 33.60%[37]. - The company reported a net loss of RMB 97,267,590.67 for the first half of 2022, compared to a net profit of RMB 79,609,151.79 in the first half of 2021[140]. - The total profit for the first half of 2022 was RMB -105,634,777.20, compared to RMB 79,969,884.67 in the first half of 2021[140]. Cash Flow and Investments - The net cash flow from investing activities was negative at approximately CNY -265.93 million, a significant increase in cash outflows for fixed and intangible asset purchases[48]. - The net cash flow from financing activities increased by 585.85% year-on-year to approximately CNY 143.91 million, mainly due to increased cash from loans[48]. - Cash and cash equivalents at the end of the period increased by 59.39% year-on-year to approximately CNY 254.72 million, driven by higher cash receipts from sales[50]. - The cash outflow for investing activities was CNY 270,932,444.52 in the first half of 2022, significantly higher than CNY 69,146,196.99 in the first half of 2021, indicating increased investment activity[145]. - The cash inflow from financing activities increased to CNY 306,620,000.00 in the first half of 2022, up from CNY 200,000,000.00 in the first half of 2021, marking a 53.3% increase[145]. Operational Performance - The chemical segment produced 273,700 tons of urea and sold 287,900 tons, while methanol production was 168,700 tons with sales of 163,000 tons[37]. - Urea sales volume increased by 1,100 tons year-on-year, with an average selling price rising by 748.02 yuan/ton[37]. - Methanol sales volume increased by 12,400 tons year-on-year, with an average selling price rising by 210.16 yuan/ton[37]. - The pharmaceutical segment generated an operating revenue of 53 million yuan, with a profit of -60 million yuan[37]. - The pharmaceutical manufacturing process is strictly regulated to comply with GMP guidelines, ensuring product quality throughout production[28]. - The company is focusing on developing the market for its unique medical insurance product, the heavy-leaf detoxification tincture, with a long-term cultivation plan[31]. Research and Development - The company increased R&D investment to 49.025 million yuan, accounting for 3.72% of Tongzi Chemical's revenue, and completed several projects that resulted in significant cost savings, including a 50% reduction in ammonia consumption for denitrification[39]. - Research and development expenses rose by 53.08% year-on-year to approximately CNY 56.38 million, reflecting increased investment in R&D activities[48]. - The company is enhancing its R&D capabilities to ensure a complete product structure in its pharmaceutical business[63]. - The company is advancing the R&D of several products, including Donepezil Hydrochloride Tablets and Tranexamic Acid Injection, which are currently in the approval process and are expected to enhance competitive advantages in bidding and hospital evaluations[42]. Environmental Compliance - The subsidiary Tongzi Chemical has installed online monitoring systems for wastewater and air emissions, ensuring all discharge indicators meet standards[72]. - In the first half of the year, Tongzi Chemical emitted 364.357 tons of sulfur dioxide, 206.443 tons of nitrogen oxides, and 26.860 tons of particulate matter, all within permitted limits[75]. - The wastewater treatment facility at Shengjitang Pharmaceutical has a daily processing capacity of 140 tons, effectively treating wastewater to meet discharge standards[76]. - The company has established a comprehensive environmental monitoring system to ensure compliance with environmental regulations[72]. - The company monitored wastewater discharge with a total volume of 5,492 tons in the first half of 2022, with COD at 0.064 tons and ammonia nitrogen at 0.0148 tons, both within regulatory limits[79]. Corporate Governance - The company has made changes in its board of directors, including the appointment of a new independent director[68]. - The company has committed to maintaining the independence of its financial operations, ensuring separate financial departments and accounting systems post-restructuring[99]. - The company guarantees that its senior management will not hold positions in related companies outside of their roles in the listed company, ensuring personnel independence[99]. - The company has established measures to ensure the independence of its operational management and internal structures[99]. Legal and Regulatory Matters - The company has not reported any major litigation or arbitration matters during the reporting period[104]. - The total amount involved in litigation cases reached CNY 6,646,608.4, with various companies owing amounts including CNY 2,464,782 and CNY 3,816,921 for unpaid goods and interest[106]. - The controlling shareholder, Guizhou Yuyang Trading Co., Ltd., received a public reprimand from the Shanghai Stock Exchange for failing to fulfill performance compensation commitments[108]. Market and Competitive Landscape - The company faces risks related to raw material coal supply due to national capacity reduction policies, leading to a long-term tight supply in the coal market[58]. - The price of raw coal has remained high, increasing production costs for the company, with significant impacts expected from changes in coal import volumes and domestic supply-demand dynamics[59]. - The domestic urea market is experiencing high prices, but a potential oversupply in the second half of the year may lead to price corrections[59].

2022 年第一季度报告 证券代码：600227 证券简称：圣济堂 贵州圣济堂医药产业股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 | | --- | --- | --- | | | | 增减变动幅度(%) | | 营业收入 | 576,148,030.63 | 30.88 | | 归属于上市公司股东的净利润 | -87,046,720.08 | 不适用 | | 归属于上市公司股东的扣除非经常性损益的净利润 | -86,350,677.32 | 不适 ...

Financial Performance - The company's operating revenue for 2021 was CNY 2,181,369,746.32, representing a 13.21% increase compared to CNY 1,926,852,891.74 in 2020[21]. - The net profit attributable to shareholders was -CNY 51,868,730.39, a decrease from a profit of CNY 55,605,342.41 in the previous year[22]. - The cash flow from operating activities was CNY 276,666,953.35, showing a 4.58% increase from CNY 264,557,038.82 in 2020[22]. - The total assets at the end of 2021 were CNY 4,602,167,789.46, a decrease of 1.14% from CNY 4,655,407,666.13 at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 1.71% to CNY 3,165,129,156.69 from CNY 3,220,207,150.01 in 2020[22]. - The cumulative profit available for distribution to shareholders was -CNY 206,639.58 million, indicating no cash dividends or stock bonuses for 2021[5]. - The company reported a basic earnings per share of -0.0306 yuan, a decrease from 0.0328 yuan in 2020[23]. - The company achieved a total production of 585,500 tons of urea in 2021, representing a year-on-year increase of 5.13%[33]. - The company achieved operating revenue of 218,136.97 million RMB, with a net profit attributable to the parent company of -5,186.87 million RMB, and a net profit excluding non-recurring gains and losses of -5,722.22 million RMB[78]. Revenue and Sales - The total operating revenue for the first quarter was 440.2 million yuan, with a year-on-year increase of 71%[25]. - The total revenue for the second quarter reached 591.62 million yuan, marking a 12% increase from the first quarter[25]. - The company reported a total revenue of RMB 13,783.31 million, a decrease of 62.61% compared to the previous year[120]. - The revenue from Western medicine was RMB 11,844.65 million, reflecting a significant decline of 59.04% year-on-year[121]. - Urea sales revenue was CNY 1,185,490,529.36, with a gross margin of 23.64%, reflecting a decrease in profitability[84]. Market Conditions - The domestic urea market in 2021 experienced price fluctuations, with prices reaching historical highs due to supply-demand imbalances and inflation[41]. - Urea prices reached historical highs in the second and third quarters of 2021, driven by supply constraints and increased demand, despite a decline in demand in August due to export policy tightening[42]. - The average price of compound fertilizer in 2021 was 2,744 RMB/ton, with significant price increases observed throughout the year[48]. - The pharmaceutical industry is entering a low-profit era due to the normalization of centralized procurement, with average price reductions exceeding 50% for certain drugs[160]. - The company is experiencing a competitive landscape in the fertilizer industry, with traditional fertilizer market share declining and a need for increased energy and resource efficiency[157]. Research and Development - The company applied for 25 intellectual property rights in 2021, including 1 invention patent and 24 utility model patents, all of which received acceptance notifications[35]. - The company’s research and development expenses increased due to higher investment in R&D by the chemical segment, indicating a focus on innovation[81]. - The company reported a research and development investment of 215.44 million RMB, accounting for 7.47% of operating revenue[127]. - The company's R&D investment capitalized ratio is 9.33%, indicating a significant portion of R&D costs are recognized as intangible assets[127]. - The company is focusing on new product development and cost control to maintain profitability in a challenging regulatory environment[160]. Operational Challenges - The company faced non-operating fund occupation by controlling shareholders and related parties[7]. - The company is facing challenges in the pharmaceutical sector due to stricter regulations and policy changes affecting production and sales[87]. - The company is facing risks related to coal supply shortages and price increases, which significantly impact production costs due to high coal dependency[166]. - The implementation of "carbon peak" and "carbon neutrality" policies poses challenges for traditional chemical production companies, requiring increased investment in energy efficiency and carbon reduction[167]. Strategic Initiatives - The company has established a robust sales network across major cities in China, enhancing its market presence and brand recognition through various promotional strategies[67]. - The company is actively pursuing partnerships to leverage synergies and enhance its product portfolio[179]. - The company plans to implement a new compensation scheme for senior management starting January 1, 2022, as approved by the board[186]. - The company is exploring potential acquisitions to enhance its product portfolio and distribution channels[185]. - The company is committed to enhancing product quality management in response to stricter regulatory requirements and increased responsibilities for drug manufacturers[160]. Management and Governance - The total pre-tax remuneration for the chairman, Ding Linhong, was CNY 564,000[177]. - The total pre-tax remuneration for the vice chairman, Zhou Junsheng, was CNY 572,700[177]. - The company has established a comprehensive governance structure to ensure independence from its controlling shareholders, maintaining operational autonomy[173]. - Financial independence is upheld through a complete and compliant financial accounting system, with no shared banking arrangements with controlling entities[174]. - The company has implemented measures to prevent fund occupation by controlling shareholders, ensuring financial integrity and operational independence[173].

Financial Performance - The company's operating revenue for 2021 was CNY 2,181,369,746.32, representing a 13.21% increase compared to CNY 1,926,852,891.74 in 2020[21]. - The net profit attributable to shareholders was a loss of CNY 51,868,730.39, compared to a profit of CNY 55,605,342.41 in the previous year[22]. - The cash flow from operating activities was CNY 276,666,953.35, showing a 4.58% increase from CNY 264,557,038.82 in 2020[22]. - The total assets at the end of 2021 were CNY 4,602,167,789.46, a decrease of 1.14% from CNY 4,655,407,666.13 at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 1.71% to CNY 3,165,129,156.69 from CNY 3,220,207,150.01 in 2020[22]. - The cumulative undistributed profits as of December 31, 2021, were CNY -206,639.58 million, indicating no conditions for profit distribution[5]. - The company did not declare cash dividends or bonus shares for the year 2021 due to negative distributable profits[5]. - The company reported a basic earnings per share of -0.0306 CNY for 2021, a decrease from 0.0328 CNY in 2020[23]. - The company’s net profit attributable to shareholders was -5,186.87 million RMB, with a net profit excluding non-recurring items of -5,722.22 million RMB[78]. Operational Highlights - The total operating revenue for the fourth quarter was 526,307,352.98 CNY, with a year-over-year increase of 51% compared to the third quarter[25]. - The net profit attributable to shareholders for the fourth quarter was -170,561,532.5 CNY, a significant decline from 36,513,639.5 CNY in the third quarter[25]. - The company achieved a total operating revenue of 203,019.57 million CNY in its chemical business, reflecting a year-over-year increase of 31.53%[32]. - The average coal procurement price surged to 2200 CNY per ton in the fourth quarter, impacting the company's operational costs[33]. - The effective production time for the chemical business was 340 days in 2021, a decrease of 4.5% compared to 2020[33]. - The company produced 58.55 million tons of urea in 2021, representing a year-over-year increase of 5.13%[33]. - The company reported a cash flow from operating activities of 114,553,375 CNY in the first quarter of 2021[26]. - The company plans to enhance production management and optimize operational processes to mitigate external adverse impacts[33]. Market and Industry Trends - The domestic urea market in 2021 experienced price fluctuations, with prices reaching historical highs due to supply-demand mismatches and inflation factors[41]. - In 2021, the total production of urea in China was 53.699 million tons, a slight decrease of 0.06% compared to 2020[43]. - Urea prices reached historical highs in the second and third quarters of 2021, driven by supply constraints and increased demand, despite a decline in demand in August due to export policy tightening[42]. - The average price of compound fertilizer in 2021 was 2,744 RMB/ton, with significant price increases observed throughout the year[48]. - The production capacity of methanol in China was 96.74 million tons in 2021, reflecting a year-on-year growth of 3.54%[54]. - The actual methanol production in 2021 was 78.9995 million tons, an increase of 9.45% compared to 2020[54]. - The overall market for urea is influenced by both positive and negative factors, with global food security concerns likely to have a greater positive impact[48]. - The domestic methanol market experienced significant fluctuations, with prices reaching historical highs due to various market pressures, including high coal prices and supply constraints[53]. Research and Development - The company applied for 25 intellectual property rights in 2021, including 1 invention patent and 24 utility model patents, all of which received acceptance notices[35]. - The company’s research and development expenses increased by 32.02% to 95,625.80 million RMB, indicating a commitment to enhancing product development[81]. - Total R&D investment reached 97,907,255.58 CNY, which is 4.49% of operating revenue, with capitalized R&D accounting for 2.33%[93]. - The number of R&D personnel is 148, making up 12.63% of the total workforce[94]. - The company has made significant advancements in the development of drugs for various conditions, including diabetes and hypertension, with several projects in the final stages of research[123]. - The company is actively pursuing regulatory approvals for new products, with several applications currently under review by the National Medical Products Administration[125]. - The company has established a robust governance structure to ensure independence from its controlling shareholders, maintaining operational autonomy[173]. Strategic Initiatives - The company is focusing on new product development and technological advancements to meet evolving market demands[180]. - The company is exploring partnerships to expand its market reach and enhance product offerings[180]. - The company is investing heavily in R&D, with a budget allocation of 100 million yuan for the development of new pharmaceutical technologies[184]. - The company is actively expanding its presence in the internet healthcare sector, supported by government policies aimed at promoting telemedicine services[162]. - The company is committed to enhancing quality management and regulatory compliance in response to stricter oversight in the pharmaceutical industry[161]. - The company plans to produce 581,800 tons of urea, 357,500 tons of methanol, and 24.53 million boxes (bottles, units) of pharmaceuticals in 2022, with an expected revenue of 2,521.87 million yuan and a projected total profit of -191.42 million yuan[166]. Corporate Governance and Management - The total pre-tax remuneration for the chairman, Ding Linhong, was CNY 564,000[178]. - The total pre-tax remuneration for the vice chairman, Zhou Junsheng, was CNY 572,700[178]. - The total pre-tax remuneration for the independent director, Shi Yucheng, was CNY 100,000[178]. - The total pre-tax remuneration for the independent director, Liu Jian, was CNY 100,000[178]. - The total pre-tax remuneration for the independent director, Wang Pu, was CNY 100,000[178]. - The total pre-tax remuneration for the supervisor, Dai Xuanzhong, was CNY 262,300[178]. - The total pre-tax remuneration for the board secretary, Xian Zhenghong, was CNY 402,700[178]. - The total pre-tax remuneration for the financial director, Wu Huan, was CNY 147,000[178]. - The total pre-tax remuneration for the deputy general manager, Chen Honglin, was CNY 367,400[178]. - The total pre-tax remuneration for the deputy general manager, Yang Yang, was CNY 0[178]. - The company has not faced any penalties from securities regulatory agencies in the past three years[189]. - The total number of employees in the parent company is 66, while the main subsidiaries employ 1,161, resulting in a total of 1,227 employees[200].

公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 2021 年第三季度报告 证券代码：600227 证券简称：圣济堂 贵州圣济堂医药产业股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | 年初至报告期末 | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 623,238,078.51 | 39.34 | 1,655,062,393.34 | ...

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥1,031,824,314.83, representing a 35.84% increase compared to ¥759,573,252.65 in the same period last year[17]. - Net profit attributable to shareholders was ¥82,179,162.56, a significant increase of 455.01% from ¥14,806,882.45 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥80,439,843.90, up 1,069.87% from ¥6,875,968.48 in the same period last year[17]. - The net cash flow from operating activities was ¥221,795,134.90, an increase of 13.20% compared to ¥195,928,214.08 in the previous year[17]. - Basic earnings per share for the first half of 2021 were ¥0.0485, up 457.47% from ¥0.0087 in the same period last year[18]. - The diluted earnings per share also stood at ¥0.0485, reflecting the same percentage increase as basic earnings per share[18]. - The weighted average return on net assets was 2.52%, an increase of 2.05 percentage points compared to 0.47% in the previous year[18]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,776,525,963.19, reflecting a 2.60% increase from ¥4,655,407,666.13 at the end of the previous year[17]. - The net assets attributable to shareholders increased to ¥3,303,636,042.67, a 2.59% rise from ¥3,220,207,150.01 at the end of the previous year[17]. - Cash and cash equivalents increased by 97.71% to CNY 238,458,253.98, representing 4.99% of total assets[50]. - Accounts receivable decreased by 6.98% to CNY 860,141,853.18, accounting for 18.01% of total assets[50]. - Inventory rose by 20.89% to CNY 256,297,329.06, making up 5.37% of total assets[50]. - Total liabilities of the company as of June 30, 2021, were CNY 1,465,764,000.70, compared to CNY 1,425,504,585.53 at the end of 2020, reflecting a slight increase of 2.8%[128]. Revenue Breakdown - The chemical segment generated operating revenue of 969 million yuan and a profit of 93 million yuan, while the pharmaceutical segment reported revenue of 63 million yuan and a loss of 13 million yuan[38]. - Revenue increased by 272 million yuan compared to the same period last year, primarily due to a 35,100-ton increase in urea sales volume and an average selling price increase of 220.78 yuan per ton[39]. - The sales revenue from diabetes medications accounted for over 80% of the pharmaceutical segment, with the industry maintaining a stable gross profit margin of 46.1%[31]. Market and Industry Insights - The company’s chemical products, particularly urea, are positioned within the nitrogen fertilizer sub-industry, which is a key area of focus for growth[26]. - The global adult diabetes patient population is projected to increase by 24.8% to 578 million by 2030, indicating significant market opportunities for domestic companies[32]. - The pharmaceutical sector reported a decrease in the loss ratio, with 1,900 out of 8,232 companies in the industry reporting losses, resulting in a loss ratio of 23.0%, down 1 percentage point from the previous month[31]. Environmental Compliance - Environmental monitoring indicates that the company’s subsidiary, Tongzi Chemical, meets all emission standards for pollutants, ensuring compliance with environmental regulations[68]. - The total wastewater discharge in the first half of the year was 10,800 m³, with COD at 0.155 tons and ammonia nitrogen at 0.0018 tons[74]. - The company achieved compliance in all monitored emissions, including an average noise level of 57.20 dB(A) during the day at the northern boundary, below the limit of 60 dB(A)[69]. Research and Development - Research and development expenses rose by 26.71% to approximately ¥36.83 million, reflecting the progress of the Zhongguan Biotech R&D project[48]. - The company is actively developing the market for Methimazole enteric-coated tablets, aiming to increase its market share in response to high demand[43]. - The company has a competitive edge in the diabetes medication market with multiple product approvals, including metformin and glimepiride, and is expanding its product line with new developments[33]. Corporate Governance and Management - The company has experienced changes in its senior management, including the appointment of a new CFO and the election of a new employee representative supervisor[64]. - The company has committed to not transferring shares acquired through asset transactions for a period of 36 months[85]. - The company has implemented strict internal control systems to ensure steady development in its pharmaceutical business[60]. Shareholder Information - The company has a total of 70,934 common shareholders as of the end of the reporting period[116]. - The largest shareholder, Guizhou Yuyang Trading Co., Ltd., holds 447,733,356 shares, accounting for 26.44% of the total shares[118]. - The company distributed cash dividends of RMB 0.5 per 10 shares (including tax) and increased its total share capital to 950,392,526 shares after the bonus issue[166].

Financial Performance - The company's operating revenue for 2020 was approximately ¥1.93 billion, a decrease of 4.91% compared to ¥2.03 billion in 2019[21]. - The net profit attributable to shareholders was approximately ¥55.61 million, a significant recovery from a net loss of approximately ¥1.71 billion in 2019[21]. - The cash flow generated from operating activities increased by 88.84% to approximately ¥264.56 million, compared to ¥140.09 million in 2019[22]. - Total assets at the end of 2020 were approximately ¥4.66 billion, a slight decrease of 1.06% from ¥4.71 billion at the end of 2019[22]. - The company's retained earnings as of December 31, 2020, were negative at approximately -¥202.92 million, resulting in no cash dividends or stock bonuses for the year[5]. - Basic earnings per share for 2020 was CNY 0.0328, a significant recovery from a loss of CNY -1.0098 in 2019[23]. - The weighted average return on equity increased to 1.74% in 2020 from -42.69% in 2019[23]. - The company reported a net cash flow from operating activities of CNY 76,419,556.21 for the year, down from CNY 119,508,657.87 in 2019[25]. Operational Highlights - The company is focusing on strategic development and operational goals, with detailed risks discussed in the report[7]. - The company has not engaged in any non-compliant guarantees, ensuring adherence to regulatory requirements[7]. - The company’s pharmaceutical segment focuses on diabetes treatment products and has five exclusive proprietary drug products[31]. - The chemical segment operates a production base with an annual capacity of 520,000 tons of urea and 300,000 tons of methanol[31]. - The procurement strategy emphasizes market-based operations and cost reduction while ensuring quality[31]. - The company plans to dynamically adjust production and procurement plans based on sales performance and market conditions[32]. - The company maintains a market share of 70-80% in the Guizhou urea market, with an annual demand of approximately 500,000 to 550,000 tons[39]. Market Trends - In 2020, the average operating rate of China's urea production facilities was around 60%, with a total output of 53.73 million tons, an increase of 1.95% compared to 2019[36]. - The company’s methanol production capacity exceeds 300,000 tons annually, with a focus on markets in Guizhou and Guangxi, leveraging stable coal supply and low production costs[39]. - In 2020, China's urea import volume was approximately 0.16 million tons, a significant decrease of about 99.1% compared to 2019, while exports reached around 5.45 million tons, an increase of about 10%[36]. - The urea market in 2020 experienced price fluctuations, with a notable increase in prices during the second half of the year, despite being lower than 2019 levels overall[35]. Pharmaceutical Sector Insights - The pharmaceutical manufacturing industry in China generated revenue of CNY 1,955.6 billion in the first ten months of 2020, with a year-on-year growth of 2.5%[40]. - The total profit of the pharmaceutical manufacturing industry reached CNY 277.9 billion in 2020, reflecting a year-on-year increase of 8.7%[40]. - The global adult diabetes patient population was 463 million in 2019, projected to rise to 578 million by 2030 (+24.8%) and 700 million by 2045 (+51.2%)[41]. - The diabetes medical expenditure was approximately USD 760 billion in 2019, expected to increase to USD 825 billion by 2030 and USD 845 billion by 2045[41]. - The company’s main revenue source comes from diabetes medications, including Metformin and Glimepiride, with a significant market share in public hospitals[42]. - The company has a competitive advantage with nearly 7 diabetes drug approvals and a strong customer base developed over 20 years[42]. Research and Development - The company has implemented technological innovations that reduced the comprehensive electricity consumption of ammonia production from 521 kWh/ton in 2019 to 440 kWh/ton in 2020[44]. - The total R&D investment amounted to 91,489,980.14 yuan, representing 4.75% of total revenue, with 148 R&D personnel accounting for 12.20% of total staff[70]. - The company is actively expanding its product line, with ongoing R&D for several new pharmaceutical products, including Acarbose tablets and various injectable solutions[56]. - The company has a robust pipeline of new drug applications, with several products expected to receive regulatory approval in the coming years, enhancing future revenue potential[87]. Compliance and Governance - The company has committed to maintaining strict compliance with regulations and has not reported any breaches of commitments during the reporting period[152]. - The company guarantees the independence and integrity of its assets, ensuring that its operations remain completely independent from other controlled entities[156]. - The company has established a commitment to fair and reasonable pricing for any necessary related party transactions[156]. - The company has committed to transparency in its financial dealings and adherence to regulatory requirements[156]. Environmental Responsibility - The company has implemented strict pollution control measures, ensuring that environmental protection facilities operate simultaneously with production processes[192]. - The company has adhered to the "three simultaneous" principle in environmental impact assessments for new projects, ensuring compliance with environmental regulations[193]. - The total emissions of sulfur dioxide were 428.920 tons, nitrogen oxides were 341.945 tons, and particulate matter was 50.465 tons, all below the approved limits[187]. - The average concentration of sulfur dioxide emissions was 112.5 mg/m³, well within the standard limit of 400 mg/m³[186].